This company listing is no longer active
McKesson Europe Inkomsten in het verleden
Verleden criteriumcontroles 0/6
McKesson Europe's earnings have been declining at an average annual rate of -2039.3%, while the Healthcare industry saw earnings growing at 3.8% annually. Revenues have been growing at an average rate of 8.7% per year.
Belangrijke informatie
-2,039.3%
Groei van de winst
-2,039.3%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 15.7% |
| Inkomstengroei | 8.7% |
| Rendement op eigen vermogen | -2.0% |
| Nettomarge | -0.6% |
| Laatste winstupdate | 31 Mar 2022 |
Recente prestatie-updates uit het verleden
Recent updates
Estimating The Fair Value Of McKesson Europe AG (HMSE:CLS1)
Dec 23
These Return Metrics Don't Make McKesson Europe (HMSE:CLS1) Look Too Strong
Sep 01These Return Metrics Don't Make McKesson Europe (HMSE:CLS1) Look Too Strong
May 19McKesson Europe (HMSE:CLS1) Could Be Struggling To Allocate Capital
Jan 27Capital Allocation Trends At McKesson Europe (HMSE:CLS1) Aren't Ideal
Sep 07McKesson Europe (HMSE:CLS1) Will Be Looking To Turn Around Its Returns
Apr 29What You Need To Know About McKesson Europe AG's (HMSE:CLS1) Investor Composition
Mar 20Is McKesson Europe AG (HMSE:CLS1) A Risky Dividend Stock?
Feb 13
Opbrengsten en kosten
Hoe McKesson Europe geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 22 | 9,257 | -54 | 450 | 0 |
| 31 Mar 21 | 8,518 | 3 | 484 | 0 |
| 31 Mar 20 | 17,118 | -71 | 1,146 | 0 |
| 31 Mar 19 | 16,417 | -47 | 1,159 | 0 |
| 31 Mar 18 | 21,090 | -303 | 1,416 | 0 |
| 31 Mar 17 | 20,644 | -807 | 1,260 | 0 |
| 31 Dec 16 | 20,475 | -76 | 2,333 | 0 |
| 30 Sep 16 | 21,118 | 437 | 1,354 | 0 |
| 30 Jun 16 | 21,265 | 459 | 1,387 | 0 |
| 31 Mar 16 | 21,193 | 487 | 1,428 | 0 |
| 31 Mar 15 | 21,076 | 129 | 1,352 | 0 |
| 31 Dec 14 | 20,647 | 187 | 1,347 | 0 |
| 30 Sep 14 | 21,877 | 79 | 1,454 | 0 |
| 30 Jun 14 | 21,606 | 64 | 1,443 | 0 |
| 31 Mar 14 | 21,426 | 167 | 1,422 | 0 |
| 31 Dec 13 | 21,408 | 165 | 1,419 | 0 |
| 30 Sep 13 | 21,565 | 146 | 1,392 | 0 |
| 30 Jun 13 | 21,753 | 153 | 1,389 | 0 |
| 31 Mar 13 | 21,990 | 99 | 1,418 | 0 |
| 31 Dec 12 | 22,271 | 103 | 1,428 | 0 |
| 30 Sep 12 | 22,339 | 51 | 1,447 | 0 |
| 30 Jun 12 | 22,347 | 72 | 1,440 | 0 |
Kwaliteitswinsten: CLS1 is currently unprofitable.
Groeiende winstmarge: CLS1 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: Insufficient data to determine if CLS1's year-on-year earnings growth rate was positive over the past 5 years.
Versnelling van de groei: Unable to compare CLS1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: CLS1 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-23.9%).
Rendement op eigen vermogen
Hoge ROE: CLS1 has a negative Return on Equity (-1.96%), as it is currently unprofitable.